JPH09509572A - 抗原をベースとしたヘテロポリマー類及びそれを使用する自己免疫疾患治療法 - Google Patents
抗原をベースとしたヘテロポリマー類及びそれを使用する自己免疫疾患治療法Info
- Publication number
- JPH09509572A JPH09509572A JP7522419A JP52241995A JPH09509572A JP H09509572 A JPH09509572 A JP H09509572A JP 7522419 A JP7522419 A JP 7522419A JP 52241995 A JP52241995 A JP 52241995A JP H09509572 A JPH09509572 A JP H09509572A
- Authority
- JP
- Japan
- Prior art keywords
- ahp
- antibody
- antigen
- human
- red blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.霊長類赤血球上の補体レセプター(CR1)部位に特異的に結合するモノク ローナル抗体を包含する、抗原をベースとしたヘテロポリマー(AHP)複合体 であって、前記モノクローナル抗体が標的病原性抗体または自己抗体に特異的な 抗原に架橋結合されている、抗原ベース・ヘテロポリマー複合体。 2.モノクローナル抗体が、1B4、HB8592、および7G9で構成される グループから選ばれる、請求項1に記載のAHP。 3.標的抗体または自己抗体が次の抗原、即ち、第VIII因子、筋肉アセチルコリ ンレセプター、カルジオリピン、血小板に関係する蛋白質類、シェーグレン症候 群に関係する抗原類、2本鎖デオキシリボ核酸(dsDNA)、および1本鎖D NA(ssDNA)、に対する抗体または自己抗体で構成されるグループから選 ばれるものである、請求項1に記載のAHP。 4.前記抗原が、第VIII因子、筋肉アセチルコリンレセプター、カルジオリピン 、血小板に関係する蛋白質類、シェーグレン症候群に関係する抗原類、2本鎖デ オキシリボ核酸(dsDNA)、および1本鎖DNA(ssDNA)で構成され るグループから選ばれる、請求項1に記載のAHP。 5.少なくとも2種のAHPを包含するAHPカクテルであって、当該AHPが 霊長類赤血球上の補体レセプター(CR1)部位に特異的に結合するモノクロー ナル抗体を包含し、且つ当該モノクローナル抗体が標的病原性抗体または自己抗 体に特異的な抗原に架橋結合されているものである、AHPカクテル。 6.自己免疫疾患を治療する方法であって、 1)ヒトまたは非ヒト霊長類に臨床的有効量のAHPを投与し、ただし当該AH Pは霊長類赤血球上の補体レセプター(CR1)部位に特異的に結合するモノク ローナル抗体を包含し、且つ当該モノクローナル抗体が標的病原性抗体または自 己抗体に特異的な抗原に架橋結合されているものであり、 2)前記AHPを、少なくとも1個の競合CR1部位と、前記病原性抗体または 自己抗体に結合させ、 3)前記の結合されたAHPを、前記ヒトまたは非ヒト霊長類の循環系から一掃 されるようにする、上記各段階を包含する治療方法。 7.モノクローナル抗体が、1B4、HB8592、および7G9で構成される グループから選ばれる、請求項6に記載の方法。 8.標的抗体または自己抗体が次の抗原、即ち、第VIII因子、筋肉アセチルコリ ンレセプター、カルジオリピン、血小板に関係する蛋白質類、シェーグレン症候 群に関係する抗原類、2本鎮デオキシリボ核酸(dsDNA)、および1本鎖D NA(ssDNA)、に対する抗体または自己抗体で構成されるグループから選 ばれるものである、請求項6に記載のAHP。 9.前記抗原が、第VIII因子、筋肉アセチルコリンレセプター、カルジオリピン 、血小板に関係する蛋白質類、シェーグレン症候群に関係する抗原類、2本鎖デ オキシリボ核酸(dsDNA)、および1本鎖DNA(ssDNA)で構成され るグループから選ばれる、請求項6に記載のAHP。 10.AHPをヒトまたは非ヒト霊長類に対して経静脈的に、臨床的有効量投与 する、請求項6に記載の方法。 11.前記AHPをヒトに対して経静脈的に、1〜10mgの臨床的有効量を投 与する、請求項10に記載の方法。 12.前記臨床的有効量のAHPの前記投与が、前記ヒトまたは非ヒト霊長類の 循環系から病原性抗体または自己抗体が完全に一掃されるまで繰り返される、請 求項6に記載の方法。 13.前記標的病原性抗体または自己抗体が霊長類の循環系から一掃され、かつ 前記赤血球は循環系中を再循環される、請求項6に記載の方法。 14.自己免疫疾患を治療する方法であって、 1)ヒトまたは非ヒト霊長類に、少なくとも2種のAHPを包含するAHPカ クテルを臨床的有効量投与し、ただしそれぞれのAHPは霊長類赤血球上の補体 レセプター(CR1)部位に特異的に結合するモノクローナル抗体を包含し、且 つ当該モノクローナル抗体が標的病原性抗体または自己抗体に特異的な抗原に架 橋結合されているものであり、 2)前記AHPカクテルを、少なくとも1個の競合CR1部位と、前記病原性 抗体または自己抗体に結合させ、そして 3)前記の結合されたAHPカクテルを、前記ヒトまたは非ヒト霊長類の循環 系から一掃されるようにする、上記各段階を包含する治療方法。 15.自己免疫疾患を治療する方法であって、 1)ヒトまたは非ヒト霊長類赤血球をAHPで無害化させ、ただし当該AHP は霊長類赤血球上の補体レセプター(CR1)部位に特異的に結合するモノクロ ーナル抗体を包含し、且つ当該モノクローナル抗体が標的病原性抗体または自己 抗体に特異的な抗原に架橋結合されているものであり、 2)ヒト又は非ヒト霊長類に臨床的有効量のAHP無害化赤血球を投与し、 3)前記AHPを前記病原性抗体または自己抗体に結合させ、そして 4)前記の結合されたAHPを、前記ヒトまたは非ヒト霊長類の循環系から一 掃されるようにする、上記各段階を包含する治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20257294A | 1994-02-28 | 1994-02-28 | |
US202,572 | 1994-02-28 | ||
PCT/US1995/002165 WO1995022977A1 (en) | 1994-02-28 | 1995-02-28 | Antigen-based heteropolymers and method for treating autoimmune diseases using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09509572A true JPH09509572A (ja) | 1997-09-30 |
Family
ID=22750436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7522419A Pending JPH09509572A (ja) | 1994-02-28 | 1995-02-28 | 抗原をベースとしたヘテロポリマー類及びそれを使用する自己免疫疾患治療法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US5879679A (ja) |
EP (1) | EP0743856B1 (ja) |
JP (1) | JPH09509572A (ja) |
AT (1) | ATE245030T1 (ja) |
AU (1) | AU696964B2 (ja) |
CA (1) | CA2183535A1 (ja) |
DE (1) | DE69531290T2 (ja) |
DK (1) | DK0743856T3 (ja) |
ES (1) | ES2207646T3 (ja) |
PT (1) | PT743856E (ja) |
WO (1) | WO1995022977A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013541504A (ja) * | 2010-08-10 | 2013-11-14 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル) | 赤血球結合療法 |
JP2015508770A (ja) * | 2012-02-15 | 2015-03-23 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合治療剤 |
US10265415B2 (en) | 2010-08-10 | 2019-04-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Compositions for inducing antigen-specific tolerance |
US10800838B2 (en) | 2010-08-10 | 2020-10-13 | École Polytechnique Fédérale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
JP2021502958A (ja) * | 2017-10-20 | 2021-02-04 | シーエスエル、リミテッド | 方法 |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU696964B2 (en) * | 1994-02-28 | 1998-09-24 | University Of Virginia Patent Foundation | Antigen-based heteropolymers and method for treating autoimmune diseases using the same |
WO2001041813A2 (en) | 1999-11-28 | 2001-06-14 | La Jolla Pharmaceutical Company | Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
AU4155602A (en) * | 2000-11-01 | 2002-06-18 | Elusys Therapeutics Inc | Method of producing biospecific molecules by protein trans-splicing |
AU2002306728B2 (en) * | 2001-03-15 | 2007-12-13 | Elusys Therapeutics, Inc. | Polyclonal populations of bispecific molecules and methods of production and uses thereof |
CA2454226A1 (en) * | 2001-07-17 | 2003-01-30 | University Of Virginia Patent Foundation | Improved heteropolymer complexes and methods for their use |
US20030114405A1 (en) * | 2001-08-13 | 2003-06-19 | Linnik Matthew D. | Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function |
WO2003018774A2 (en) * | 2001-08-29 | 2003-03-06 | University Of Virginia Patent Foundation | Therapeutic uses of complement receptor 2 |
US7105135B2 (en) * | 2001-10-16 | 2006-09-12 | Lockheed Martin Corporation | System and method for large scale detection of hazardous materials in the mail or in other objects |
EP1576100A4 (en) * | 2002-05-13 | 2007-08-22 | Elusys Therapeutics Inc | PURIFIED COMPOSITION OF BISPECIFIC MOLECULES AND METHODS OF PRODUCING THE SAME |
EP1539199A4 (en) * | 2002-06-13 | 2008-07-02 | Cygene Inc | PROCEDURE AND COMPOSITIONS FOR IN VIVO ELIMINATION OF ENTREPRENEURS |
AU2003295330A1 (en) * | 2002-09-16 | 2004-05-04 | Elusys Therapeutics, Inc. | Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
US20040208864A1 (en) * | 2002-12-27 | 2004-10-21 | Vibeke Strand | Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
WO2004087759A2 (en) * | 2003-03-28 | 2004-10-14 | Elusys Therapeutics, Inc. | Method and compositions for conversion of antibody activity |
WO2004089422A2 (en) * | 2003-03-30 | 2004-10-21 | La Jolla Pharmaceutical Co. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
EP1622938A1 (en) | 2003-05-09 | 2006-02-08 | University Of Massachusetts Medical Center | Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor |
US9493538B2 (en) * | 2004-05-28 | 2016-11-15 | University Of Massachusetts | Snares for pathogenic or infectious agents and uses related thereto |
JP2008518947A (ja) * | 2004-10-29 | 2008-06-05 | エルシス セラピューティクス, インク. | 免疫応答のクリアランス及び誘導におけるcr1結合分子の使用 |
AU2006311661B2 (en) | 2005-11-07 | 2011-05-26 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
US8828077B2 (en) * | 2006-03-15 | 2014-09-09 | Medinol Ltd. | Flat process of preparing drug eluting stents |
FR2968304B1 (fr) * | 2010-12-01 | 2014-03-14 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | Nouveaux epaississants cationiques, exempts d'huile et de tensioactifs, procede pour leur preparation et composition en contenant. |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
ES2874884T3 (es) | 2014-02-21 | 2021-11-05 | Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto | Compuestos terapéuticos dirigidos a la glucosa |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8869291A (en) * | 1990-10-04 | 1992-04-28 | University Of Virginia Alumni Patents Foundation, The | Primate erythrocyte bound monoclonal antibody heteropolymers |
AU696964B2 (en) * | 1994-02-28 | 1998-09-24 | University Of Virginia Patent Foundation | Antigen-based heteropolymers and method for treating autoimmune diseases using the same |
-
1995
- 1995-02-28 AU AU19677/95A patent/AU696964B2/en not_active Ceased
- 1995-02-28 EP EP95912577A patent/EP0743856B1/en not_active Expired - Lifetime
- 1995-02-28 JP JP7522419A patent/JPH09509572A/ja active Pending
- 1995-02-28 AT AT95912577T patent/ATE245030T1/de not_active IP Right Cessation
- 1995-02-28 DK DK95912577T patent/DK0743856T3/da active
- 1995-02-28 PT PT95912577T patent/PT743856E/pt unknown
- 1995-02-28 WO PCT/US1995/002165 patent/WO1995022977A1/en active IP Right Grant
- 1995-02-28 CA CA002183535A patent/CA2183535A1/en not_active Abandoned
- 1995-02-28 ES ES95912577T patent/ES2207646T3/es not_active Expired - Lifetime
- 1995-02-28 DE DE69531290T patent/DE69531290T2/de not_active Expired - Fee Related
- 1995-06-05 US US08/460,861 patent/US5879679A/en not_active Expired - Fee Related
-
2001
- 2001-10-26 US US10/016,763 patent/US20020103343A1/en not_active Abandoned
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013541504A (ja) * | 2010-08-10 | 2013-11-14 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル) | 赤血球結合療法 |
JP2017008046A (ja) * | 2010-08-10 | 2017-01-12 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合療法 |
US10265415B2 (en) | 2010-08-10 | 2019-04-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Compositions for inducing antigen-specific tolerance |
US10265416B2 (en) | 2010-08-10 | 2019-04-23 | École Polytechnique Fédérale de Lausanna (EPFL) | Compositions for generation of immune tolerance to specific antigens |
US10471155B2 (en) | 2010-08-10 | 2019-11-12 | École Polytechnique Fédérale De Lausanne (Epfl) | Antigen-specific tolerance and compositions for induction of same |
US10800838B2 (en) | 2010-08-10 | 2020-10-13 | École Polytechnique Fédérale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
JP2015508770A (ja) * | 2012-02-15 | 2015-03-23 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合治療剤 |
JP2018127458A (ja) * | 2012-02-15 | 2018-08-16 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合治療剤 |
JP2020147591A (ja) * | 2012-02-15 | 2020-09-17 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合治療剤 |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
JP2021502958A (ja) * | 2017-10-20 | 2021-02-04 | シーエスエル、リミテッド | 方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0743856B1 (en) | 2003-07-16 |
EP0743856A4 (en) | 2000-04-12 |
ES2207646T3 (es) | 2004-06-01 |
US5879679A (en) | 1999-03-09 |
WO1995022977A1 (en) | 1995-08-31 |
EP0743856A1 (en) | 1996-11-27 |
PT743856E (pt) | 2003-12-31 |
ATE245030T1 (de) | 2003-08-15 |
DE69531290T2 (de) | 2004-05-13 |
US20020103343A1 (en) | 2002-08-01 |
DE69531290D1 (de) | 2003-08-21 |
AU1967795A (en) | 1995-09-11 |
AU696964B2 (en) | 1998-09-24 |
DK0743856T3 (da) | 2003-11-10 |
CA2183535A1 (en) | 1995-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09509572A (ja) | 抗原をベースとしたヘテロポリマー類及びそれを使用する自己免疫疾患治療法 | |
US5487890A (en) | Mammalian primate erythrocyte bound heteropolymerized monoclonal antibodies and methods of use thereof | |
EP0728215B1 (en) | METHOD OF BINDING MATERIAL TO THE Beta-AMYLOID PEPTIDE | |
JP2021100408A (ja) | 自己免疫疾患の治療及び/又は診断におけるアプタマーの使用 | |
US6569431B2 (en) | Recombinant antibody fragments as autoantibody antagonists | |
WO2022063892A1 (en) | Compound for increasing efficacy of viral vectors | |
AU2002211771A1 (en) | Recombinant antibody fragments as autoantibody antagonists | |
JPS61143328A (ja) | リンパ節疾患及び後天性免疫不全症候群の病因物質からtリンパ球を保護するための組成物及び方法 | |
US20210403897A1 (en) | Chemical engineering of erythrocytes to display polypeptides and other biomacromolecules | |
Nardin et al. | Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes | |
Sundewall et al. | Acetylcholine receptor antibodies in primary biliary cirrhosis: characterization of antigen and idiotypic specificity | |
JP2004532626A (ja) | 二重特異性分子のポリクローナル集団、ならびにそれらの産生方法および使用 | |
TWI238251B (en) | In-vitro adsorbing device using immunity | |
UA60331C2 (uk) | Спосіб лікування розсіяного склерозу | |
Lin et al. | Single-Cell Heterogeneity Restorative Chimeric Engineering Nanoparticles for Alleviating Antibody-Mediated Allograft Injury | |
AU2021348226A1 (en) | Compound for the sequestration of undesirable anti-peg antibodies in a patient | |
CN116710143A (zh) | 用于预防或治疗重症肌无力的化合物 | |
CN116669771A (zh) | 用于隔离患者体内不需要的抗peg抗体的化合物 | |
Kornhuber et al. | Experimental Models of Superantigen‐Mediated Neuropathology | |
Wiesenhutter | COMBINATION OF PROSORBA® IMMUNOADSORPTION FOLLOWED BY B-CELL DEPLETION WITH RITUXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS AN INDEPENDENT OPEN CLINCIAL TRIAL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040720 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041020 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050119 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050809 |